Fair Value Calculator Fair Value Calculator
EN DE

EKAMLEA (EKAMLEA) Fair Value & Analysis

IN · Market cap ₹45.8M

E EKAMLEA EKAMLEA · BSE
Price₹7.64
Fair Value₹4.07
Upside-46.7%
Quality48/100
Watch EKAMLEA for free — get notified when fair value or trend changes. Watch for free
Evidence: Low Range ₹2.69 – ₹5.09

Fair value as of: Jul 5, 2026

From 1 valuation models · updated today

Share price +5.8% over the past month.

Price vs Fair Value (12 months)

₹8.45 ₹4.81 Fair Value ₹4.07 Jul 2025 Jul 2026

12‑month range ₹4.81 – ₹8.45 · fair‑value band ₹2.69 – ₹5.09 · the ₹7.64 price screens above the ₹4.07 fair value. As of Jul 5, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

EKAMLEA (EKAMLEA) currently trades at ₹7.64, while our model-based Fair Value estimate is ₹4.07 — implying the stock looks roughly 46.7% overvalued today. We read business quality at 48/100 (below-average quality). Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Trailing-twelve-month revenue stands at ₹1.3M. Revenue grew 68.0% year over year. It earns a return on equity of -69.8%. Net debt stands at ₹18.3M. Fundamentals as of Jul 5, 2026

Our scenario range runs from ₹2.69 (bear case) to ₹5.09 (bull case); at ₹7.64, the current price sits above that range. The share trades about 14% below its 52-week high and 59% above its 52-week low, currently above its 200-day average.

Key figures & financial health

Revenue (TTM) ₹1.3M
Revenue growth (YoY) +68.0%
Return on equity -69.8%
Free cash flow −₹8.8M FY2026
Operating margin -2,161%
EPS (TTM) ₹-6.84
More key figures
Net debt ₹18.3M FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

EKAMLEA reported revenue of ₹765K in FY2026 versus ₹6.3M in FY2022, a compound −41.0%/yr. Reported net income was −₹41.1M in FY2026.

Revenue −41.0%/yr
FY22 ₹6.3M
FY23 ₹6.8M
FY24 ₹7.3M
FY25 ₹3.4M
FY26 ₹765K
Net income
FY22 ₹2.5M
FY23 −₹1.8M
FY24 ₹6.3M
FY25 −₹9.7M
FY26 −₹41.1M

Is EKAMLEA fairly valued? → Check now

🧮 Run the numbers yourself — free valuation calculators
📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog — it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "EKAMLEA Fair Value". https://www.fairvalue-calculator.com/stock/EKAMLEA

Explore undervalued stocks

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is EKAMLEA (EKAMLEA) undervalued?
As of Jul 5, 2026, our model estimates a fair value of ₹4.07 versus a price of ₹7.64 — about −47% (overvalued). Model-based estimate, not financial advice.
What is the fair value of EKAMLEA?
Our model-based fair value for EKAMLEA is ₹4.07 (as of Jul 5, 2026), built from audited fundamentals. The current price is ₹7.64.
What is the quality score of EKAMLEA?
EKAMLEA has a Quality Score of 48/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of EKAMLEA (EKAMLEA)?
EKAMLEA reported trailing-twelve-month revenue of about ₹1.3M (latest available figure, as of Jul 5, 2026).
What is the net profit margin of EKAMLEA?
The net profit margin of EKAMLEA is about 0.0%, meaning it keeps roughly 0.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.